TCT 2025 - Three-year findings from LIFE-BTK show the Esprit™ BTK scaffold is a durable and effective treatment option for patients with CLTI.

Dr Sahil Parikh (Columbia University Vagelos College of Physicians & Surgeons, New York, US) joins us to share the three-year findings from LIFE-BTK (NCT04227899). The randomized controlled trial aimed to evaluate the safety and efficacy of the Esprit™ BTK everolimus-eluting resorbable scaffold compared to percutaneous transluminal angioplasty (PTA) treatment for infrapopliteal lesions.

Findings suggested clinical advantage over PTA across three years of study, with a 33% improvement in the composite endpoint of limb salvage and primary patency, and a 45% reduction in clinically-driven target lesion revascularizaion in favour of the Esprit™ BTK device.

Interview Questions:

1. What is the reasoning behind the LIFE-BTK trial?
2. Could you tell us about the unique features of the Esprit™ BTK scaffold?
3. What was the study design and patient population?
4. What were the key three-year findings from the LIFE-BTK trial?
5. What do these results mean for practice, and what’s next for follow-up?

Recorded on-site at TCT Conference in San Francisco, 2025.
Editor: Yazmin Sadik
Video Specialist: Tom Green, Mike Knight

Support: This is an independent interview produced by Transcatheter Academy.